AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
New Fortress Energy
NFE
Cars.com
CARS
4
Halozyme Therapeutics
HALO
5
Collegium Pharmaceutical
COLL
US Stock MarketDetailed Quotes
CARM Carisma Therapeutics
- 0.414
- -0.002-0.51%
Close Mar 21 16:00 ET
17.27MMarket Cap-0.27P/E (TTM)
0.420High0.390Low48.90KVolume0.410Open0.416Pre Close19.98KTurnover0.16%Turnover RatioLossP/E (Static)41.75MShares2.30052wk High-1.56P/B12.50MFloat Cap0.38052wk Low--Dividend TTM30.22MShs Float51.357Historical High--Div YieldTTM7.22%Amplitude0.380Historical Low0.408Avg Price1Lot Size
Carisma Therapeutics News
Carisma Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Klichinsky Michael
Carisma Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kelly Steven
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer McAndrew Natalie
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 10-Q: Q3 2024 Earnings Report
Carisma Therapeutics | 8-K: Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Cheng Sohanya Roshan
Carisma Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Cheng Sohanya Roshan
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 10-Q: Q2 2024 Earnings Report
Carisma Therapeutics | 8-K: Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Thorell Marella
Carisma Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Scadden David
Carisma Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Thorell Marella
Market Insights
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call